Board Meeting other than Financial Result of GlaxoSmithKline Pakistan Limited

Karachi, GlaxoSmithKline Pakistan Limited informed Pakistan Stock Exchange that board of directors meeting of the company will be held on June 19, 2019 at Karachi to consider the approval of D-MERPS implementation process as initiated by GSK plc.

Further, the company has declared the closed period from June 12, 2019 to June 19, 2019.

Glaxo Smith Kline Pakistan Limited is incorporated in Pakistan as a limited liability company. The company is engaged in manufacturing and marketing of research based pharmaceutical and consumer products. The company is a subsidiary of S.R. One International B.V., Netherlands, whereas its ultimate parent company is GlaxoSmithKline Plc, UK. The stocks of the company are quoted on the Karachi and Lahore Stock Exchanges of Pakistan.

The company was created on January 1, 2001 through the merger of SmithKline and French of Pakistan Limited, Beecham Pakistan Private Limited and Glaxo Wellcome Pakistan Limited. Some of the pharmaceutical brands produced by the company include Augmentin, Seretide, Amoxil, Velosef, Zantac and Calpol and renowned consumer healthcare brands, which include Panadol, Horlicks, Aquafresh, Macleans and ENO.

The symbol “GLAXO” is being used by the stock exchanges for the shares of GlaxoSmithKline Pakistan Limited.